6564.TWO Enimmune corporation

Healthcare Biotechnology Taiwan OTC Exchange
13.75 TWD
Close of Nov 6, 2026
13.55 22.55
Market cap
TWD 996M
P/E
-
P/B
10.47x
ROE
-109.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6564.TWO undervalued?

Graham number

The Graham number of Enimmune corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Enimmune corporation fundamental analysis

No fundamental analysis for Enimmune corporation yet.

Enimmune corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Enimmune corporation

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syn…

Full company profile